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Background
Adoptive immunotherapy with genetically modified
T cells holds promise in improving outcomes for cancer
patients. While a broad array of genetic modification
strategies are being explored, few allow for the specific
manipulation of adoptively transferred T cells in vivo.
One successful example includes the introduction of an
inducible ‘suicide gene’ to enable selective T-cell killing
in the event of toxicities. Given the limited antitumor
activity of adoptively transferred T cells for solid tumors
in early clinical studies, we reasoned that introducing an
inducible co-stimulatory molecule into T cells would
allow for the selective activation of adoptively trans-
ferred T cells in vivo resulting in enhanced antitumor
activity. Due to the role of MyD88 and CD40 signaling
pathways to fine tune T-cell activation, and the recent
success of using inducible (i) MyD88 and CD40 mole-
cules to activate antigen-presenting cells, the goal of this
project was to explore if T cells can be activated with
iMyD88 and/or iCD40 molecules.
Methods/results
We constructed a panel of retroviral vectors encoding
mOrange as a marker gene and an inducible co-stimula-
tory molecule (iCO-STIM) consisting of a myristoylation
tag, two FKBP dimerizer domains, and i) MyD88,
ii) CD40, or iii) MyD88 + CD40. T cells expressing
iMyD88, iCD40, or iMyD88.CD40 were generated by
retroviral transduction, and transduction was confirmed
by FACS analysis and Western blot. T cells expressing
iCO-STIMs were activated with the CD3 monoclonal
antibody OKT3 in the presence or absence of the che-
mical inducer of dimerization (CID), AP20187. iMyD88.
CD40 T cells secreted the highest amount of IL2 in the
presence of OKT3 + CID in comparison to iMyD88 or
iCD40 T cells. To evaluate if activating iMyD88.CD40 in
CAR T cells also enhances cytokine production, we gen-
erated T cells that expressed HER2-CARs and iMyD88.
CD40 (HER2-CAR/iCO-STIM T cells). CID enhanced
IL2 production of HER2-CAR/iCOSTIM T cells that
were either stimulated with recombinant HER2 protein
or HER2+ cell lines. Enhanced IL2 production was
observed with 1st, 2nd, and 3rd generation HER2-CARs.
Conclusion
We have generated CAR T cells with an inducible co-
stimulatory molecule based on MyD88 and CD40. Preli-
minary functional analysis of CAR/iCO-STIM T cells is
encouraging, warranting further active exploration of this
approach to improve current T-cell therapy approaches
for cancer.
Authors’ details
1Baylor College of Medicine, Houston, TX, USA. 2Bellicum Pharmaceuticals
and Baylor College of Medicine, Houston, TX, USA. 3Department of
Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine,
Houston, TX, USA.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P118
Cite this article as: Mata et al.: MyD88/CD40-based inducible co-
stimulation to improve CAR T cell therapy. Journal for ImmunoTherapy of
Cancer 2015 3(Suppl 2):P118.
1Baylor College of Medicine, Houston, TX, USA
Full list of author information is available at the end of the article
Mata et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P118
http://www.immunotherapyofcancer.org/content/3/S2/P118
© 2015 Mata et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
